- IN₹229.07bn
- IN₹234.65bn
- IN₹53.66bn
Brief: Granules Unit Receives FDA Tentative Approval For Generic Amphetamine With 180-Day Exclusivity
Brief: Granules To Issue Warrants Upto 14.63 Billion Rupees
Brief: Granules Says Raising Of Funds Through Issuance Of Shares Worth Up To 3 Billion Rupees
Brief: Granules Says Unit Gets USFDA Tentative Approval For Generic Amphetamine Extended-Release Orally Disintegrating Tablets
Brief: Granules Says FDA Inspection At Unit Concludes With Five Observations
Brief: Granules Unit Receives Eir From FDA
Brief: Granules's Packaging Facility In US Completes FDA Inspection With Zero Observations
Brief: Granules Incorporates Subsidiary In Canada
Brief: Granules Approved Acquisition Of 100% Stake In Optus 1039 GmbH
Granules India posts higher quarterly profit on strong North America, Europe sales
Brief: Granules India Q2 Consol Profit 1.31 Bln Rupees
Brief: Granules - Granules Life Sciences Receives U.S. FDA Approval For Hyderabad Facility
Granules India rises on securing US regulatory clearance
Paracetamol maker Granules India's quarterly profit drops on supply backlog
Brief: Granules India Q1 Consol Profit 1.13 Billion Rupees
Brief: NSE To Exclude F&O Contracts On 8 Securities Including Adani Total Gas, Jindal Stainless From Aug 29 On Expiry Of Existing Contracts
Brief: Granules India Says Bonthapally Facility Completes US FDA Inspection
Paracetamol maker Granules India's profit drops as lower prices in US, Europe pinch
Brief: Granules India Q4 Consol Profit 1.52 Billion Rupees